

**ATTACHMENT C**

## CONTACT REPORT FORM

**Person Contacted: Ken Deegan, Director,  
Sales and Marketing**

**Co. Name: Kenilworth Pharmaceuticals,  
division of Schering-Plough (Schering)**

**Date: 1/11/06**

**Phone #: (908) 629-3615**

**Contacted By: Everett Carmody, President**

**Co. Name: SPEC Pharma**

**Date: 1/11/06**

**Phone #: (512) 751-1641**

**RE: Availability of Celestone® Soluspan®**

### **BACKGROUND:**

A recent press release from Schering indicated that the firm has completed the steps and validation actions required by Dec. 31, 2005, under its consent decree. I contacted various drug wholesalers to determine the effect of this notice on the availability of the drug product and was informed that availability was no longer limited.

### **SUMMARY:**

I called Ken Deegan, Director of Sales and Marketing for Kenilworth Pharmaceuticals [the division of Schering-Plough (Schering) responsible for the production of Celestone® Soluspan®] to inquire about the current availability of the drug product based on the recent press release and information received from drug wholesaler contacts.

Mr. Deegan did confirm that there are currently no restrictions on the availability of Celestone® Soluspan®. Mr. Deegan did not comment as to whether the Food and Drug Administration had completed their review of the submitted information.